STAT+: M&A is back, but nothing in biotech is neat or simple
The biotech mood check lately? Happy, says STAT's Adam Feuerstein.
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Biotech mood check: Happy
Two acquisitions. Strong drug launches. FDA drug approvals. A rebounding XBI now 18% higher from its recent low.
All in, a very pleasant week so far.
